Cyclo(-RGDfK)

Research use only, not for human use.

A RGD pipetide, potent and selective αvβ3 integrin inhibitor with Kd of 41.7 nM.

A RGD pipetide, potent and selective αvβ3 integrin inhibitor with Kd of 41.7 nM; shows strong inhibitory effect on the proliferation of T-24 cells; induces less tumor progression, less tumor metabolic activity, fewer intratumoral vessels in mice model.(In Vitro):Cyclo(-RGDfK) is a potent and selective inhibitor of the αvβ3 integrin, with a IC50 of 0.94 nM. [66Ga]DOTA-E-[c(RGDfK)]2 can be prepared with high radiochemical purity (>97%), specific activity (36-67GBq/μM), in vitro stability, and moderate protein binding. MicroPET imaging up to 24 post-injection showed contrasting tumors reflecting αvβ3-targeted tracer accumulation.

Cyclo(-RGDfK) is a potent and selective inhibitor of the αvβ3 integrin, with a IC50 of 0.94 nM. [66Ga]DOTA-E-[c(RGDfK)]2 can be prepared with high radiochemical purity (>97%), specific activity (36-67GBq/μM), in vitro stability, and moderate protein binding. MicroPET imaging up to 24 post-injection showed contrasting tumors reflecting αvβ3-targeted tracer accumulation.

——

Cyclo(RGDfK) peptide | Cyclic RGDfK peptide

Cell Cycle/DNA Damage

Integrin

αVβ3integrin

Cancer

——

161552-03-0

603.6705

C27H41N9O7

>98% (HPLC)

DMSO: ≥150 mg/mL

C1C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)CCCN=C(N)N)CCCCN)CC2=CC=CC=C2)CC(=O)O

Cyclo(L-arginylglycyl-L-α-aspartyl-D-phenylalanyl-L-lysyl)

(-20℃)

With Ice Pack

≥ 2 years